Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BMY Bristol-Myers Squibb	$46.88 -0.3%	$51.79	$39.35 ▼ $63.33	$95.40B	0.39	13.17 million shs	8.40 million shs
PFE Pfizer	$23.33 +1.3%	$23.38	$20.92 ▼ $31.54	$132.66B	0.58	41.03 million shs	35.31 million shs
UCBJF UCB	$175.75	$165.24	$149.85 ▼ $209.66	$33.22B	0.47	603 shs	N/A
VRTX Vertex Pharmaceuticals	$436.00 +0.5%	$476.26	$377.85 ▼ $519.88	$111.96B	0.51	1.42 million shs	1.43 million shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BMY Bristol-Myers Squibb	-0.23%	+0.24%	-3.34%	-16.05%	+10.70%
PFE Pfizer	+1.36%	+2.23%	+4.26%	-11.33%	-21.17%
UCBJF UCB	0.00%	+4.21%	+16.62%	-7.29%	+33.14%
VRTX Vertex Pharmaceuticals	+0.45%	-0.60%	-11.46%	-9.96%	-2.58%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BMY Bristol-Myers Squibb	4.6246 of 5 stars	3.2	3.0	4.2	4.0	3.5	3.3	0.0
PFE Pfizer	4.9465 of 5 stars	3.3	3.0	4.2	4.3	3.3	1.7	3.1
UCBJF UCB	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VRTX Vertex Pharmaceuticals	4.6126 of 5 stars	3.3	5.0	0.0	3.3	4.2	2.5	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BMY Bristol-Myers Squibb	2.32	Hold	$58.00	23.72% Upside
PFE Pfizer	2.53	Moderate Buy	$29.17	25.00% Upside
UCBJF UCB	0.00	N/A	N/A	N/A
VRTX Vertex Pharmaceuticals	2.59	Moderate Buy	$515.04	18.13% Upside

Current Analyst Ratings Breakdown

Latest UCBJF, PFE, VRTX, and BMY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/7/2025	VRTX Vertex Pharmaceuticals	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Peer Perform
5/6/2025	VRTX Vertex Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/6/2025	VRTX Vertex Pharmaceuticals	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/6/2025	VRTX Vertex Pharmaceuticals	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
5/6/2025	VRTX Vertex Pharmaceuticals	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Perform ➝ Sector Perform	$450.00 ➝ $442.00
5/6/2025	VRTX Vertex Pharmaceuticals	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Perform ➝ Sector Perform	$420.00 ➝ $423.00
5/6/2025	VRTX Vertex Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$462.00 ➝ $464.00
5/6/2025	VRTX Vertex Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$512.00 ➝ $515.00
5/6/2025	VRTX Vertex Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$535.00 ➝ $535.00
5/6/2025	VRTX Vertex Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform	$550.00 ➝ $503.00
4/30/2025	PFE Pfizer	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$24.00 ➝ $25.00

(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BMY Bristol-Myers Squibb	$47.64B	2.00	$4.95 per share	9.48	$8.08 per share	5.80
PFE Pfizer	$62.46B	2.12	$3.66 per share	6.38	$15.81 per share	1.48
UCBJF UCB	$5.27B	6.31	$7.55 per share	23.28	$50.52 per share	3.48
VRTX Vertex Pharmaceuticals	$11.10B	10.09	N/A	N/A	$63.90 per share	6.82

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BMY Bristol-Myers Squibb	-$8.95B	$2.67	N/A	7.70	2.07	-18.53%	13.93%	2.46%	7/25/2025 (Estimated)
PFE Pfizer	$8.03B	$1.38	16.55	7.70	0.64	12.62%	19.47%	8.09%	7/29/2025 (Estimated)
UCBJF UCB	$371.23M	N/A	0.00	24.89	N/A	N/A	N/A	N/A	7/23/2025 (Estimated)
VRTX Vertex Pharmaceuticals	-$535.60M	-$3.92	N/A	24.90	2.11	-4.86%	-2.02%	-1.49%	8/7/2025 (Estimated)

Latest UCBJF, PFE, VRTX, and BMY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/5/2025	Q1 2025	VRTX Vertex Pharmaceuticals	$4.29	$4.06	-$0.23	$2.49	$2.85 billion	$2.77 billion
4/29/2025	Q1 2025	PFE Pfizer	$0.67	$0.92	+$0.25	$0.52	$14.43 billion	$13.72 billion
4/24/2025	Q1 2025	BMY Bristol-Myers Squibb	$1.50	$1.80	+$0.30	$1.21	$10.77 billion	$11.20 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BMY Bristol-Myers Squibb	$2.48	5.29%	+6.38%	92.88%	17 Years
PFE Pfizer	$1.72	7.37%	+2.50%	124.64%	16 Years
UCBJF UCB	N/A	N/A	N/A	N/A	N/A
VRTX Vertex Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Latest UCBJF, PFE, VRTX, and BMY Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/23/2025	PFE Pfizer	quarterly	$0.43	7.69%	5/9/2025	5/9/2025	6/13/2025
3/3/2025	BMY Bristol-Myers Squibb	quarterly	$0.62	4.14%	4/4/2025	4/4/2025	5/1/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BMY Bristol-Myers Squibb	2.90	1.25	1.15
PFE Pfizer	0.63	1.00	0.73
UCBJF UCB	0.33	1.19	0.78
VRTX Vertex Pharmaceuticals	0.01	2.69	2.35

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BMY Bristol-Myers Squibb	76.41%
PFE Pfizer	68.36%
UCBJF UCB	N/A
VRTX Vertex Pharmaceuticals	90.96%

Insider Ownership

Company	Insider Ownership
BMY Bristol-Myers Squibb	0.07%
PFE Pfizer	0.06%
UCBJF UCB	N/A
VRTX Vertex Pharmaceuticals	0.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BMY Bristol-Myers Squibb	34,300	2.04 billion	2.03 billion	Optionable
PFE Pfizer	83,000	5.69 billion	5.66 billion	Optionable
UCBJF UCB	9,083	189.02 million	N/A	Not Optionable
VRTX Vertex Pharmaceuticals	4,800	256.80 million	256.28 million	Optionable

UCBJF, PFE, VRTX, and BMY Headlines

Recent News About These Companies

2 Monster Growth Stocks to Buy and Hold for 10 Years

May 24 at 1:05 PM | fool.com

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Sold by JT Stratford LLC

May 24 at 7:03 AM | marketbeat.com

Harmony Asset Management LLC Has $2.53 Million Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

May 24 at 6:26 AM | marketbeat.com

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Sold by Voloridge Investment Management LLC

May 24 at 5:23 AM | marketbeat.com

Castleark Management LLC Sells 36,240 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

May 23 at 7:52 AM | marketbeat.com

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Bought by BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp

May 23 at 7:44 AM | marketbeat.com

USS Investment Management Ltd Sells 2,996 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

May 23 at 6:42 AM | marketbeat.com

Zurich Insurance Group Ltd FI Reduces Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

May 23 at 6:07 AM | marketbeat.com

Westwood Holdings Group Inc. Makes New $1.28 Million Investment in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

May 23 at 5:58 AM | marketbeat.com

Principal Street Partners LLC Cuts Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

May 22 at 8:00 AM | marketbeat.com

Lantern Wealth Advisors LLC Buys 650 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

May 22 at 7:40 AM | marketbeat.com

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Trims Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

May 22 at 7:19 AM | marketbeat.com

Woodline Partners LP Acquires 16,653 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

May 22 at 6:17 AM | marketbeat.com

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Acquired by Vident Advisory LLC

May 22 at 5:59 AM | marketbeat.com

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Stock Holdings Lifted by Tidal Investments LLC

May 22 at 5:17 AM | marketbeat.com

Vertex Pharmaceuticals Stock Outlook: Is Wall Street Bullish or Bearish?

May 21 at 4:44 PM | msn.com

Westport Asset Management Inc. Takes Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

May 21 at 7:15 AM | marketbeat.com

Triglav Skladi D.O.O. Takes $1.39 Million Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

May 21 at 6:55 AM | marketbeat.com

Twinbeech Capital LP Purchases New Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

May 21 at 6:54 AM | marketbeat.com

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Purchased by Silvercrest Asset Management Group LLC

May 21 at 5:42 AM | marketbeat.com

Tema Etfs LLC Takes $4.42 Million Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

May 20, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?
By Jeffrey Neal Johnson | April 25, 2025
View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?
Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for Long
By Sam Quirke | May 13, 2025
View Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for Long
Why D-Wave's Project With Davidson Is a Game-Changer For Quantum
By Nathan Reiff | April 30, 2025
View Why D-Wave's Project With Davidson Is a Game-Changer For Quantum
NVIDIA Stock Surges on Bullish News: How High Could It Climb?
By Thomas Hughes | May 13, 2025
View NVIDIA Stock Surges on Bullish News: How High Could It Climb?
Pfizer's 7.5% Dividend: Income Haven or House of Cards?
By Jeffrey Neal Johnson | May 23, 2025
View Pfizer's 7.5% Dividend: Income Haven or House of Cards?

UCBJF, PFE, VRTX, and BMY Company Descriptions

Bristol-Myers Squibb NYSE:BMY

$46.88 -0.15 (-0.32%)

Closing price 05/23/2025 03:59 PM Eastern

Extended Trading

$46.88 +0.00 (+0.01%)

As of 05/23/2025 07:33 PM Eastern

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Pfizer NYSE:PFE

$23.33 +0.29 (+1.28%)

Closing price 05/23/2025 03:59 PM Eastern

Extended Trading

$23.33 0.00 (-0.02%)

As of 05/23/2025 08:00 PM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

UCB OTCMKTS:UCBJF

$175.75 0.00 (0.00%)

As of 05/23/2025

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx for treating plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis; and Fintepla to treat Dravet syndrome. In addition, the company is involved in developing rozanolixizumab and Zilbrisq to treat myasthenia gravis; dapirolizumab pegol for systemic lupus erythematosus; fenfluramine to treat CDKL5 deficiency disorder; doxecitine for TK2 deficiency disorder; STACCATO alprazolam for stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; minzasolmin and UCB0222 for Parkinson's disease; and UCB1381 and UCB9741 for atropic dermatitis. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, and Otsuka. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.

Vertex Pharmaceuticals NASDAQ:VRTX

$436.00 +1.97 (+0.45%)

Closing price 05/23/2025 04:00 PM Eastern

Extended Trading

$434.46 -1.54 (-0.35%)

As of 05/23/2025 07:59 PM Eastern

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time